Zeiser, R
Burchert, A
Lengerke, C
Verbeek, M
Maas-Bauer, K
Metzelder, S K
Spoerl, S
Ditschkowski, M
Ecsedi, M
Sockel, K
Ayuk, F
Ajib, S
de Fontbrune, F S
Na, I-K
Penter, L
Holtick, U
Wolf, D
Schuler, E
Meyer, E
Apostolova, P
Bertz, H
Marks, R
Lübbert, M
Wäsch, R
Scheid, C
Stölzel, F
Ordemann, R
Bug, G
Kobbe, G
Negrin, R
Brune, M
Spyridonidis, A
Schmitt-Gräff, A
van der Velden, W
Huls, G
Mielke, S
Grigoleit, G U
Kuball, J
Flynn, R
Ihorst, G
Du, J
Blazar, B R
Arnold, R
Kröger, N
Passweg, J
Halter, J
Socié, G
Beelen, D
Peschel, C
Neubauer, A
Finke, J
Duyster, J
von Bubnoff, N
Article History
Received: 17 July 2015
Revised: 23 July 2015
Accepted: 24 July 2015
First Online: 31 July 2015
Competing interests
: FA, UH, CS, GB, JK, NK, NVB: Research support from Novartis, Bristol Meyer Squibb. DW: grants and personal fees from Novartis. RZ: Speakers fee from Bristol Meyer Squibb, travel grant from Gilead. All grants from Novartis were outside/unrelated to the submitted work. The other authors declare no conflict of interest.